接受异基因干细胞移植的急性髓系白血病患者中CD34+/CD38-细胞负荷的预后影响
该研究评估169例完全缓解期接受异基因干细胞移植的急性髓系白血病患者诊断时骨髓CD34+/CD38-细胞负荷的临床关联及预后影响,发现高负荷与较差遗传风险和继发性AML相关,且无复发生存和总生存较短,可能由逃逸移植物抗白血病效应的残留白血病起始细胞介导。
要点
- 诊断时骨髓CD34+/CD38-细胞负荷中位0.5%(范围0%-89%单核细胞)。
- 高CD34+/CD38-细胞负荷与较差遗传风险和继发性AML相关。
- 高负荷患者无复发生存和总生存较短,可能由逃逸移植物抗白血病效应的残留白血病起始细胞介导。
核心结论
- 诊断时评估CD34+/CD38-细胞负荷可能有助于识别异基因移植后高复发风险患者。
- 需要进一步研究理解白血病起始细胞生物学并开发靶向治疗以改善AML患者结局。
研究设计与样本
- 评估169例完全缓解期接受异基因干细胞移植的急性髓系白血病患者诊断时骨髓CD34+/CD38-细胞负荷的临床和生物学关联及预后影响。
主要发现
- 诊断时骨髓CD34+/CD38-细胞负荷中位0.5%(范围0%-89%单核细胞)。
- 高CD34+/CD38-细胞负荷与较差遗传风险和继发性AML相关。
- 高CD34+/CD38-细胞负荷患者无复发生存和总生存较短,可能由逃逸移植物抗白血病效应的残留白血病起始细胞介导。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究理解白血病起始细胞生物学并开发靶向治疗以改善AML患者结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In acute myeloid leukemia (AML), leukemia-initiating cells exist within the CD34+/CD38- cell compartment. They are assumed to be more resistant to chemotherapy, enriched in minimal residual disease cell populations, and responsible for relapse. Here we evaluated clinical and biological associations and the prognostic impact of a high diagnostic CD34+/CD38- cell burden in 169 AML patients receiving an allogeneic stem cell transplantation in complete remission. Here, the therapeutic approach is mainly based on immunological graft-versus-leukemia effects. Percentage of bone marrow CD34+/CD38- cell burden at diagnosis was measured using flow cytometry and was highly variable (median 0.5%, range 0%-89% of all mononuclear cells). A high CD34+/CD38- cell burden at diagnosis associated with worse genetic risk and secondary AML. Patients with a high CD34+/CD38- cell burden had shorter relapse-free and overall survival which may be mediated by residual leukemia-initiating cells in the CD34+/CD38- cell population, escaping the graft-versus-leukemia effect after allogeneic transplantation. Evaluating the CD34+/CD38- cell burden at diagnosis may help to identify patients at high risk of relapse after allogeneic transplantation. Further studies to understand leukemia-initiating cell biology and develop targeting therapies to improve outcomes of AML patients are needed.
引用
- Jentzsch M, Bill M, Nicolet D, et al. Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation. Am J Hematol. 2017. PMID: 28133783. doi:10.1002/ajh.24663
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。